Plasma P-Tau217: A Cost-Effective And Practical Surrogate Biomarker For Clinical Trials

Plasma p-tau217: a cost-effective and practical surrogate biomarker for clinical trials

Plasma versus neuroimaging biomarkers for Alzheimer’s disease clinical trials

Investigating novel plasma-based P-tau biomarkers

Plasma p-tau217 screening identifies individuals most likely to benefit from anti-amyloid therapy

Diagnostic performance of plasma p-tau217 in a memory clinic cohort

Plasma biomarkers for population-based Alzheimer’s disease screening

Plasma tau217 occupancy as accurate as validated CSF tests

Differences between Alzheimer’s disease biomarkers: p-Tau181, p-Tau231 & p-Tau217

Novel tau based immunoassay identifies Alzheimer's pathology - Presented by ALZpath

Samba Scientific

Investigating p-tau217 as a clinical screening tool

The ability of plasma P-tau231 to detect preclinical Alzheimer’s disease

Bringing plasma biomarkers into clinical practice: what does the future hold?

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Plasma p-tau as a biomarker for cerebral amyloid angiopathy diagnosis

Examining plasma vs. CSF p-tau217 in preclinical and prodromal Alzheimer’s disease

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

New Blood Test for Early Detection for Alzheimer's Disease | Plasma Biomarker P-Tau217

Peak Human Labs

Latest knowledge on plasma p-tau in Alzheimer’s disease

Blood Biomarker Challenge - There are two complementary research projects joining the challenge

Dementias Platform UK